Today: Swedish Alzheimer's Project Receives Billion-Dollar Support from Pharmaceutical Giant Eli Lilly

Alzstatin is important, not only because it is a Swedish project, but primarily because it seeks to find a method to reduce the formation of Aβ42 (plaques) from the outset, rather than clearing plaques with antibodies like Leqembi and Kisunla.

It should be noted that Lilly is not buying a finished drug in phase 3. The molecule Alzstatin ACD680 is still in a relatively early stage. Lilly is therefore investing in the technology and the mechanism behind the project.

Reduces new formation

For the Alzheimer's field, this is also a signal that Lilly believes in drugs that reduce the formation of the harmful amyloid form Aβ42, rather than trying to clear plaques retrospectively.

My interpretation is that this is one of the biggest Swedish Alzheimer's news in several years. When one of the world's most successful Alzheimer's companies – Lilly, which already has donanemab on the market – chooses to commit up to over a billion dollars to a Swedish preclinical project, it is a very strong testament that Alzstatin is perceived as scientifically interesting. This does not mean that the drug will work, but it does mean that people with far greater resources and expertise than us judge that the chance is worth a very large investment.

For us with a diagnosis

Although this news does not directly affect my treatment plan, a medicine may at best be available in ten to fifteen years, it shows that Alzheimer's no longer needs to be considered a hopeless problem.

Source

https://www.alzecurepharma.se/sv/wp-content/uploads/sites/3/2026/06/pressmeddelande-alzecure-pharma-ingar-samarbets-och-utlicensieringsavtal-med-lilly-for-alzheimerproj-260609.pdf